転移性去勢抵抗性前立腺がん（mCRPC）の治療におけるカピバセルチブ＋ドセタキセルとプラセボ＋ドセタキセルの比較研究

基本情報

NCT ID: NCT05348577
ステータス: 実施中（募集終了）
試験のフェーズ: 第3相
試験タイプ: 介入
目標被験者数: 1,035
治験依頼者名: AstraZeneca

概要

This study will assess the efficacy and safety of capivasertib plus docetaxel versus placebo plus docetaxel in participants with metastatic castration resistant prostate cancer (mCRPC), all participants will receive the docetaxel with steroid therapy and receive androgen deprivation therapy. The intention of the study is to demonstrate that the combination of capivasertib plus docetaxel is superior to placebo plus docetaxel with respect to the overall survival and/or the radiographic progression free survival of study participants.

対象疾患

Prostate Cancer

介入

capivasertib(DRUG)

docetaxel(DRUG)

placebo(OTHER)

依頼者（Sponsor）

アストラゼネカ株式会社(INDUSTRY)